BioCentury
ARTICLE | Clinical News

CTX DP: Completed Phase II enrollment

June 27, 2016 7:00 AM UTC

ReNeuron completed enrollment in the open-label, U.K. Phase II PISCES II trial evaluating CTX DP comprised of 20 million cells administered intracranially via stereotaxic neurosurgery 2-3 month after ...